Overview

Nicotinamide Riboside in Hospitalized Patients

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Patients will receive oral nicotinamide riboside or placebo and clinical and paraclinical outcome will be determined
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Oslo University Hospital
Collaborator:
ChromaDex, Inc.
Treatments:
Niacin
Niacinamide
Nicotinic Acids